Loracarbef

Drug Profile

Loracarbef

Alternative Names: KT 3777; Lorabid; Lorafem; Lorbef; LY 163892

Latest Information Update: 02 Apr 2015

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Class Antibacterials; Cephalosporins; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections

Most Recent Events

  • 01 Mar 2011 King Pharmaceuticals has been acquired and merged into Pfizer
  • 10 Apr 1996 Phase-III clinical trials for Bacterial infections in Japan (PO)
  • 14 Mar 1996 Registered for Bacterial infections in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top